Expertise in
2
conditions

Tamim M. Niazi

Montreal, QC, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
2
conditions
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Tamim Niazi practices in Montreal, Canada. Mr. Niazi is highly rated in 2 conditions, according to our data. His top areas of expertise are Prostate Cancer, Breast Enlargement In Males, Anal Cancer, Colorectal Cancer, and Prostatectomy.

His clinical research consists of co-authoring 90 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Montreal, QC, Canada
Other Locations
Gatineau, QC, Canada
Gatineau, Canada
Quebec, QC H3T1E2, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: a Pilot Phase II Trial
The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: a Pilot Phase II Trial
Enrollment Status: Recruiting
Publish Date: December 04, 2024
Intervention Type: Radiation, Drug
Study Drug: Darolutamide
Study Phase: Phase 2
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Enrollment Status: Recruiting
Publish Date: December 04, 2024
A Prospective Study Assessing the Predictive Value of TMPRSS2-ERG Gene Fusion and PTEN Deletion in High Risk Prostate Cancer Patients
A Prospective Study Assessing the Predictive Value of TMPRSS2-ERG Gene Fusion and PTEN Deletion in High Risk Prostate Cancer Patients
Enrollment Status: Withdrawn
Publish Date: December 10, 2024
A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate
A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Radiation
Study Phase: Phase 2
Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. a GROUQ Phase III Randomized Clinical Trial (PCS-VII).
Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. a GROUQ Phase III Randomized Clinical Trial (PCS-VII).
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Rapaflo, Standard Care
Study Phase: Phase 3
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy Vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy Vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2024
Intervention Type: Radiation, Drug
Study Drug: Androgen deprivation therapy
Study Phase: Phase 3
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Drug, Radiation
Study Drugs: Leuprolide acetate, Goserelin acetate, Triptorelin, Enzalutamide
Study Phase: Phase 2/Phase 3
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2023
Intervention Type: Radiation, Drug
Study Drugs: Darolutamide, Luteinizing Hormone-Releasing Hormone Analog
Study Phase: Phase 3
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
Enrollment Status: Completed
Publish Date: March 23, 2021
Intervention Type: Radiation
Study Phase: Phase 2
View 7 Less Clinical Trials

90 Total Publications

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Niazi's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile